Kelkar, Sneha S.
Prabhu, Vimalanand S. http://orcid.org/0000-0003-1358-8846
Zhang, Jingchuan
Ogando, Yoscar M.
Roney, Kyle
Verma, Rishi P.
Miles, Nicola
Marth, Christian
Funding for this research was provided by:
Merck
Eisai Incorporated
Article History
Received: 1 December 2023
Accepted: 27 March 2024
First Online: 18 April 2024
Declarations
:
: Authors report the following conflicts of interest: Sneha Kelkar, employment with OPEN Health which received consulting fees from MSD; Vimalanand Prabhu, employment with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stock with Merck & Co., Inc., Rahway, NJ, USA; Jingchuan Zhang, employment with Eisai Inc.; Yoscar Ogando, employment with OPEN Health which received consulting fees from MSD; Kyle Roney, employment with OPEN Health which received consulting fees from MSD; Rishi Verma, employment with OPEN Health which received consulting fees from MSD; Nicola Miles, employment with M3 EU Ltd.; Christian Marth, honoraria from AstraZeneca, GlaxoSmithKline, Eisai, consulting fees from AstraZeneca, GlaxoSmithKline, Eisai, advisory board participation with GlaxoSmithKline and Kartos, and support from MSD for the present manuscript.
: The studies were determined to not fall under the realm of the respective ethics committee/institutional review board oversight in each country, and the studies were granted waivers for obtaining informed consent from patients.